en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
6/2020
vol. 58
 
Share:
Share:
more
 
 
abstract:
Review paper

Baricitinib for the treatment of rheumatoid arthritis

Ivan Urits
1
,
Jacob Israel
2
,
Hayk Hakobyan
2
,
George Yusin
2
,
Grace Lassiter
2
,
Nathan Fackler
2
,
Amnon A. Berger
1
,
Hisham Kassem
3
,
Alan Kaye
4
,
Omar Viswanath
5, 6, 7

1.
Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
2.
Georgetown University School of Medicine, Washington, District of Columbia, United States
3.
Department of Anesthesiology, Mount Sinai Medical Center, Miami Beach, Florida, United States
4.
Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, Los Angeles, United States
5.
Valley Anesthesiology and Pain Consultants – Envision Physician Services, Phoenix, Arizona, United States
6.
Department of Anesthesiology, University of Arizona College of Medicine Phoenix, Phoenix, Arizona, United States
7.
Department of Anesthesiology, Creighton University School of Medicine, Omaha, Nebraska, United States
Reumatologia 2020; 58, 6: 407–415
Online publish date: 2020/12/23
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA.

This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.
keywords:

rheumatoid arthritis, novel treatment, baricitinib, Janus kinase/signaling transducer and activator of transcription, kinase inhibitor







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.